Australia tests COVID-19 vaccine, business news

US-based clinical-stage biotechnology company Novavax (NASDAQ: NVAX) has launched Phase 1 clinical trials for the COVID-19 vaccine trial, seeking expertise in the Australian-based Nucleus Network (Nucleus).

Melbourne, Australia, April 15, 2020 / PRNewswire / -First COVID-19 vaccine tested externally USA, And the world’s only third vaccine trial Australian Nucleus Network, the largest Phase 1 clinical trial specialist.

Nucleus will begin Phase 1 testing of the Novavax SARS-CoV-2 recombinant spike protein nanoparticle vaccine NVX-CoV2373 as part of an urgent global race to develop a vaccine to address the coronavirus COVID-19 outbreak. Melbourne And Brisbane Clinic within the next few weeks.

“Nucleus has a rich history of Phase 1 vaccine trials and years of experience with Novavax. We will be able to perform rapid trials in human pioneering trials over the next few weeks,” said Nucleus. Cameron johnson.

“Ability to perform this exam on both of us Melbourne And Brisbane At the clinic, Novavax will be conducting Phase 1 trials to help the NVX-CoV2373 track as quickly as possible for further development. ”

Two other recent coronavirus epidemics-Severe Acute Respiratory Syndrome (SARS) and Middle East Previous studies on respiratory syndrome (MERS) and Ebola (Phase 1 trials Australia) -Leveraging the understanding of coronaviruses, studies can be adapted to create vaccines for SARS-CoV-2, the virus that causes COVID-19.

“The urgent global competition to develop a vaccine against the COVID-19 pandemic has driven the rapid identification and selection of optimal, highly immunogenic vaccine candidates.” Stanley C. Elk, President and CEO of Novavax. “I am delighted that our long-time partner Nucleus has been able to respond to the accelerated timeline.”

The NVX-CoV2373 Phase 1 trial will begin in mid-May and preliminary immunogenicity and safety results will be published in July.

Its scale and absolute commitment make it the ideal partner for rapid development of the COVID-19 vaccine.

“We own 150 of our 250 dedicated Phase I beds. Australia Two sites Melbourne And Brisbane, In a major medical district. With the support of an employee of over 400 specialists, we are in a unique position to offer our sponsors a multi-site pass to conduct clinical trials, “Johnson says.

This scale will allow Nucleus to tackle the urgency of COVID-19 vaccine research without interrupting other ongoing clinical trials. Standards guarantee the credibility of research, especially in the current pandemic situation around the world.

“In all of our clinical trials, Nucleus has implemented the highest level of infection-prevention precautions within its clinical department, including the creation of a dedicated team of clinical staff,” said Nucleus Infectious Disease Doctors and Microbes. Scholars, and Queensland University, Doctor Paul Griffin. “These staff have been assigned to work only in functionally designated areas and there is no pollination of these teams, improving safety, reducing research risk and ensuring study integrity. doing.”

As a key partner in the development of these promising vaccine candidates, Nucleus’s role in solving the current pandemic is a top priority for Johnson.

“COVID-19 continues to affect the daily lives of all global citizens, so finding solutions is an urgent goal for governments and health organizations around the world. , We support unlocking Novavax. The potential of the Coronavirus COVID-19 vaccine. ”

Additional resources: https://nucleusnetwork.com.au/news/covid-19

About Nucleus Network

Nucleus Network is the only multi-site Phase I clinical trial provider, Australia And that USA. Nucleus Network provides biotechnology and pharmaceutical companies around the world with high quality, human-first, early-stage testing USA, Europe And Asia. Nucleus Network’s cost-effective, accelerated clinical development solutions located within the most advanced medical areas are supported by advanced technology, superior clinical and research expertise.

About Novovax

Novavax, Inc. (Nasdaq: NVAX) Globally Promotes Health Improvement Through Discovery, Development, and Commercialization of Innovative Vaccines, Prevents Serious Infectious Diseases, and Addresses Urgent Global Health Needs It is a biotechnology company. Novavax recently initiated the development of a vaccine program against COVID-19, with human results expected in July 2020. Novavax is a major innovator in recombinant vaccines. Its unique recombinant technology platform combines the power and speed of genetic engineering to efficiently generate new classes of highly immunogenic nanoparticles that address urgent global health needs.

interview:
Doctor Paul Griffin, Nuclear Infectious Disease Doctors and Microbiologists, and Associate Professor of Medicine Queensland University
Cameron johnson, Nucleus Network CEO

What all media require:
Rick Navarro, Vice President of Marketing and Business Development
[email protected]
+61 4 31 658 476

Nucleus Network Pty Ltd
Level 1, 484 St Kilda Road
Melbourne, VIC, 3004, Australia
w: nucleusnetwork.com.au

Related Links :

https://nucleusnetwork.com.au/